Objectives: Antibiotic use in French hospitals is among the highest in Europe. A study was carried out to describe antibiotic consumption for inpatients at hospital and at ward levels. Results: Median antibiotic use ranged from 60 DDD/1000 PD in long-term care (LTC) and psychiatric hospitals to 633 DDD/1000 PD in teaching hospitals. Penicillins and b-lactamase inhibitors combinations were the most frequently used antibiotics, accounting for 26% of total use in cancer hospitals to 40% in LTC/psychiatric hospitals. Glycopeptides and carbapenems were mostly used in cancer and teaching hospitals. Level of consumption and pattern of use differed according to clinical ward from 60 DDD/1000 PD in psychiatric wards up to 1466 DDD/ 1000 PD in intensive care units (ICUs). In medicine, surgery, ICU and rehabilitation wards, fluoroquinolones accounted for 13% -19% of the total use.
Introduction
France is one of the European countries where both antibiotic consumption and antimicrobial resistance are among the highest according to the European Surveillance of Antimicrobial Consumption (ESAC) project and the European Antimicrobial Resistance Surveillance System project. 1 -4 Hospital antibiotic overuse leads to the emergence of and promotes the spread of antimicrobial resistance, e.g. extended-spectrum b-lactamaseproducing or cephalosporinase-hyperproducing Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa and vancomycinresistant enterococci. 5 -7 Thus, improving antibiotic use is a key issue for infectious diseases physicians, pharmacists, microbiologists and infection control practitioners. Surveillance networks of antibiotic consumption and comparison with a benchmarking approach have proven efficacy in reducing antibiotic consumption and related bacterial resistance. 8 Thus, in the context of national programmes aimed at preventing and controlling healthcare-associated infections and antimicrobial resistance, French hospitals are urged to develop and implement antibiotic stewardship programmes to rationalize and monitor antibiotic use. 9 -13 In France, five regional Coordinating Centres for Nosocomial Infection Control (CCLIN) were created in 1992. Their missions covered healthcare-associated infections, and antimicrobial resistance prevention and control. Their main activities were: (i) to support hospitals in implementing infection control activities; (ii) to provide technical advice and expert assistance; and (iii) to develop epidemiological surveillance networks. 14 -16 In the early 2000s, CCLIN had implemented regional networks to monitor hospital antibiotic consumption and the development of antibiotic stewardship programmes. 17, 18 In 2007, the five CCLINs coordinated their networks into a national surveillance network of antibiotic consumption in French hospitals, with the objective of describing antibiotic consumption at the hospital level and the ward level, in order to provide a tool allowing comparison with a national benchmark. This paper presents the results of the 2007 surveillance.
Methods

Study design
All hospitals in four out of five regions (1959) were invited by their CCLIN to participate on a voluntary basis. Hospitals that answered positively could download an electronic questionnaire to collect the 2007 data. Nursing homes and facilities providing day care or home care only were excluded.
Data collection
Participating hospitals could provide data at the hospital level as well as at the ward level: medicine; surgery; intensive care; gynaecology; psychiatry; rehabilitation; paediatrics (including paediatric intensive care and paediatric surgery); and long-term care (LTC). Only antibiotic dispensing for inpatients was collected. Hospital pharmacies in France do not provide antibiotics for patients following discharge. Antibiotic dispensing for outpatients, prescriptions for day-care wards, consultations and dialysis were excluded from this survey.
Administrative data consisted of the hospital status, the number of beds and the number of patient days (PD) in 2007. Hospitals status was described according to French administrative classification as: teaching; non-teaching public; non-teaching private; cancer hospitals; rehabilitation centres; local hospital; LTC; and psychiatric hospitals. In France, LTC hospitals differ from nursing homes, as they deal with elderly people requiring more care than people living in nursing homes.
Antibiotic consumption data were retrieved from pharmacy records on a standardized file derived from the ABC Calc software [developed by the Danish Statens Serum Institute (http://www.escmid.org/)] on a Microsoft Excel w application (Microsoft Corporation, Redmond, WA, USA) together with administrative data. The Excel application included all antibacterial drugs marketed in France for systemic use [J01 class of the WHO Anatomical Therapeutic Chemical (ATC) classification]. 19 Since they are mainly prescribed as antibacterial drugs in the European background and since they also play a role in antimicrobial selection pressure, data on rifampicin (J04AB02) and oral nitroimidazole derivatives (P01AB class) prescribing was also collected, to better assess antimicrobial exposure. This application converted the number of dispensed units (vials, pills, capsules or bottles) into the number of daily defined doses (DDD) and then to the number of DDD/1000 PD, as recommended by the WHO, following the 2007 version of ATC/DDD classification. For the combination trimethoprim-sulfamethoxazole, DDD for the combined products was used; for drugs not covered in 2007 by the ATC/DDD classification, we used the following definition: oral cefotiam, 0.8 g; isepamicin, 1 g; and lomefloxacin, 0.4 g. By filling in the Excel w file, hospitals were simultaneously fed back with their own antibiotic consumption expressed in number of DDD/1000 PD.
Data analysis
Data at the hospital level were expressed as the pooled mean, in order to provide a global perspective of antibiotic consumption in French hospitals. Since variations in antibiotic use are linked to variations in clinical activities, 20 antibiotic use was also analysed at the ward level. Data at the ward level were expressed as a distribution [median; interquartile range (IQR)], allowing comparisons with a relevant benchmark for participants to the network. Within a class of antibiotics, the different compounds may have different indications, side effects and impact on ecological pressure. Since they are widely used and are major drivers for antimicrobial resistance, 21 the proportion of each fluoroquinolone was described. Data analysis was performed with the Microsoft Excel 
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The pattern of antibiotic use in the 530 hospitals involved in the survey varied according to hospital type ( Table 2 ). The four most frequently used groups of antibiotics were: combination of penicillins with b-lactamase inhibitors (J01CR); penicillins with extended spectrum (J01CA); fluoroquinolones (J01MA); and third-generation cephalosporins (J01DD). These antibiotics represented more than two-thirds of the total antibiotic use in all types of hospitals. The highest consumption level was observed for the combination of penicillins with b-lactamase inhibitors (J01CR), which accounted for 26% in cancer hospitals (107 DDD/1000 PD) to 40% in LTC/psychiatric hospitals (25.2 DDD/1000 PD) of total antibiotic consumption. Penicillins with extended spectrum (J01CA) ranked second, except in rehabilitation centres and cancer hospitals where fluoroquinolones did. Teaching and cancer hospitals showed a tendency to use more glycopeptides (J01XA) and carbapenems (J01DH) than other hospitals (20.9 and 18 DDD/1000 PD for glycopeptides and 12 and 7 DDD/1000 PD for carbapenems, respectively). Rehabilitation centres, local and LTC/psychiatric hospitals tended to havethe highest levels of streptogramins (J01FG) use. Overall, rifampicin (J04AB02) accounted for 3.1% of total antibiotic consumption, and was mostly used in teaching hospitals and rehabilitation centres, where it accounted for 4.6% and 5.8% of total use, respectively. Oral imidazoles (P01AB) accounted for 41% of total imidazole use and up to 3% of total antibiotic use in cancer hospitals.
Antibiotic use at ward level
Overall antibiotic use differed according to clinical ward ( Figure 2 ). Median antibiotic consumption was: 60 DDD/1000 PD in psychiatric wards; 76 DDD/1000 PD in LTC; 213 DDD/1000 PD in rehabilitation; 308 DDD/1000 PD in gynaecology; 333 DDD/ 1000 PD in paediatrics; 553 DDD/1000 PD in surgery; 583 DDD/ 1000 PD in medicine; and 1466 DDD/1000 PD in intensive care units (ICUs). The level of antibiotic consumption widely varied across similar wards (e.g. in ICUs the maximum total antibiotic use represented 7-fold the minimum value in the same area while in rehabilitation wards the range reached 89-fold).
The pattern of antibiotic use also varied among wards (Table 3) . Amoxicillin -clavulanic acid was the most common antibiotic [15% of total use (median: 253.6 DDD/1000 PD) in ICUs to 39% (median: 25.8 DDD/1000 PD) in LTC], except in paediatrics and gynaecology where amoxicillin was. The latter accounted for 11% in surgery and up to 51% in gynaecology. In medicine, surgery, ICUs and rehabilitation, fluoroquinolones accounted for 13% -19% of the total antibiotic use (median consumption: 97.8, 77.7, 192.2 and 41.5 DDD/1000 PD, respectively). In addition, the distribution of antibiotic used also varied widely from one ward to another, e.g. the proportion of fluoroquinolones among total antibiotics varied from 3.2% to 42.5% in medicine wards and from 3.4% to 49.7% in surgical wards.
Distribution of fluoroquinolones at ward level
The proportion of each fluoroquinolone varied according to clinical ward (Figure 3) . Ciprofloxacin accounted for 10% of total fluoroquinolone use in gynaecology and for 50% in ICUs. The largest proportion of levofloxacin use was observed in ICUs. Ofloxacin was the most used fluoroquinolone in gynaecology Other large multicentre surveys have been conducted, for instance in Germany 27 -29 and in the USA. 30 Some studies focused on antibiotic use in specific areas, such as ICUs. 31 -34 Our study was the first survey on a large scale describing antibiotic use at the hospital level as well as at the ward level in France. Its findings bring additional information to previously available aggregated data provided in the context of the ESAC project. The latter were obtained from hospital sales at the national level. According to those data, expressed in DDD/1000 inhabitants/day, France ranks second, after Finland. 2 In contrast, our data were expressed in number of DDD/1000 PD. Then, antibiotic use in French hospitals did not seem to be higher than those reported in other European countries: 538 DDD/1000 PD in Sweden; 609 DDD/1000 PD in the Netherlands; 749 DDD/1000 PD in Denmark; and 764 DDD/ 1000 PD in Ireland. 22, 23, 25, 26 Differences between the ESAC project and national networks on antibiotic use in hospitals may be related to the collection of sales data versus dispensing data in hospital networks (antibiotics dispensed to wards). Besides, differences between countries may result from the exclusion of psychiatric hospitals and rehabilitation centres in some countries. Another difference relates to healthcare systems: the number of hospital beds per 100000 inhabitants in 2006 was 718.3 in France, and only 287.7 in Sweden, 361.8 in Denmark, 446.1 in the Netherlands and 829.1 in Germany (http://epp.eurostat.ec. europa.eu). Also, the calculation of denominator (i.e. the number of PD or bed-days) may vary across countries. Comparisons could focus on some types of hospitals only. As already seen in Germany, higher use was seen in teaching hospitals. 27 Considering the pattern of use, French hospitals showed a high consumption of amoxicillin -clavulanic acid and amoxicillin. However, this high level of use may be overestimated because of the discrepancies between DDD and the actual prescribed daily doses, as already underscored by other authors. 33, 35, 36 In addition, high proportions of some antibiotics may be explained by the epidemiological situation regarding antimicrobial resistance. The high rate of resistance to methicillin in Staphylococcus aureus in France 3,4,37 leads to the higher use of glycopeptides and other antistaphylococcal agents, such as rifampicin and pristinamycin (which is not universally available outside France). The glycopeptide proportion among total antibiotic consumption in France was 2-fold higher than in Denmark and in Sweden in 2007. Resistance rates in Enterobacteriaceae may explain the high level of third-generation cephalosporin use observed in our study among cephalosporins, whereas first-and secondgeneration cephalosporins were widely used in Nordic countries and the Netherlands, where the use of narrow-spectrum antibiotics is more frequent than in France. However, recent reports from Denmark highlighted an increasing use of fluoroquinolones, third-generation cephalosporins and carbapenems. 22, 38 In addition to antibiotic monitoring at the hospital level, a large number of participating hospitals detailed antibiotic use at the ward level. Despite increased workload, this amount of detailed data allows more relevant analysis and provides a Dumartin et al. valuable benchmark for individual wards aware of their own consumption. Fluoroquinolone use varied according to clinical activity: in ICUs, the preferred agents were ciprofloxacin and levofloxacin, whereas in LTC norfloxacin use prevailed. These discrepancies reflect the case-mix (e.g. pneumonia in ICUs and urinary tract infections in LTC). Total antibiotic consumption in French ICUs was quite similar to that reported in Sweden. 39 However, the pattern of use differed, with higher use of carbapenems and cefuroxime in Sweden, and more fluoroquinolones and glycopeptides in France. Wide variations were also seen in the volume and pattern of antibiotic use between wards with similar clinical activity. To deepen our understanding of these variations, it would be helpful to better describe antibiotic needs by making adjustments for case-mix. 39 -41 Other factors, such as antimicrobial resistance rates and infection control resources, have an impact on antibiotic use. 25, 38 This first national survey was limited to voluntary hospitals and relied on self-reported data. Therefore, it cannot be ruled out that only those most concerned by antibiotic control participated. However, as almost 30% of French hospital beds were surveyed, and since all types of hospitals, public and private, local and teaching were involved, it can be assumed that the findings from this survey give a solid picture of the situation at the national level, consistent with nationwide antibiotic sales to hospitals. 42 Recent multicentre studies in the USA 30, 35 provided information on antibiotic consumption using days of therapy or prescribed daily doses. Such measures may be preferred to follow-up consumption over years, taking into account the real dose of drug administered to patients, and has been used in some networks, 33, 35, 36, 43, 44 given the limitations of the DDD defined by the WHO. However, we chose the latter unit of measure to allow worthwhile international comparisons, 45 and to comply with French and European guidelines. As in most national surveillance networks, 22,23,25,26 we collected dispensing data and not data on antibiotics actually administered to patients. The latter would imply access to patient records, which is not possible on a large scale. However, since data were collected in a standardized way in all hospitals, they are relevant for comparisons and to monitor trends.
Another methodological issue was the scope of the antibiotics surveyed. We included rifampicin and oral imidazole derivatives, as already done in Norway, to better reflect overall antibiotic pressure.
This national network of hospital antibiotic consumption surveillance provided hospitals with a useful tool to monitor antibiotic use and allow relevant comparisons for benchmarking. Analysis at the ward level is helpful for feedback to prescribers in order to target key areas for further investigation. Hence, in a multicentre European study in 35 ICUs, monitoring of antibiotic consumption led to audit practice and then to a dramatic decrease in the inappropriate use of antibiotics in the ICU with the highest use of antibiotics. 34 These data are also helpful for decision-and policy-makers to assess strategies for promoting prudent use of antibiotics and to identify areas needing further work. Improvements in data collection and analysis could consist of: (i) measuring activity in the number of admissions (acute care), to monitor trends taking into account changes in the length of stay over years; 22, 23, 46 and (ii) collecting other indicators of case-mix. 30, 41 Another key feature of the national network, and its management by regional CCLINs, will be its ability to carry out actions and counselling towards outlier hospitals with a high level of consumption, and to promote mutual learning from hospitals with a low level of consumption or with successful strategies to control antibiotic use.
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